Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies
Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 13, pp. 2106-2111
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Sèze, Élisabeth Maillart, Antoine Guéguen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 62
Multiple sclerosis: time for early treatment with high-efficacy drugs
Krzysztof Selmaj, Bruce Cree, Michael Barnett, et al.
Journal of Neurology (2023) Vol. 271, Iss. 1, pp. 105-115
Open Access | Times Cited: 21
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
Édouard Januel, David Hajage, Pierre Labauge, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2319766-e2319766
Open Access | Times Cited: 20
Efficacy of Rituximab Outlasts B-Cell Repopulation in Multiple Sclerosis
Roxane Claverie, Marine Perriguey, Audrey Rico, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 16
Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis
Jessica B. Smith, Edlin Gonzales, Bonnie H. Li, et al.
JAMA Network Open (2022) Vol. 5, Iss. 12, pp. e2248664-e2248664
Open Access | Times Cited: 26
Longitudinal Postvaccine SARS-CoV-2 Immunoglobulin G Titers, Memory B-Cell Responses, and Risk of COVID-19 in Multiple Sclerosis Over 1 Year
Giulio Disanto, Alice Galante, Marco Cantu', et al.
Neurology Neuroimmunology & Neuroinflammation (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 20
The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination
David Baker, Eugenia Forte, Gareth Pryce, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 69, pp. 104425-104425
Open Access | Times Cited: 19
Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
Serena Ruggieri, Alessandra Aiello, Carla Tortorella, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8525-8525
Open Access | Times Cited: 10
Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs
Rocco Capuano, Luca Prosperini, Manuela Altieri, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 7, pp. 856-865
Open Access | Times Cited: 10
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy
Daniel Sidler, Alexander Born, Simeon Schietzel, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002166-e002166
Open Access | Times Cited: 16
Antibody response elicited by the SARS‐CoV‐2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Irene Schiavetti, Matilde Inglese, Jessica Frau, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 8, pp. 2357-2364
Open Access | Times Cited: 8
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Luca Prosperini, Georgina Arrambide, Elisabeth Gulowsen Celius, et al.
The Lancet Regional Health - Europe (2024) Vol. 44, pp. 100979-100979
Open Access | Times Cited: 2
COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore
Tianrong Yeo, Rachel Wan En Siew, Muhammad Yaaseen Gulam, et al.
Journal of Neurology (2023) Vol. 270, Iss. 6, pp. 2817-2825
Open Access | Times Cited: 7
Risk of COVID-19 in people with multiple sclerosis who are seronegative following vaccination
Safiya A Zaloum, Callum H Wood, Pooja Tank, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 8, pp. 979-989
Open Access | Times Cited: 6
Preserved T cell but attenuated antibody response in MS patients on fingolimod and ocrelizumab following 2nd and 3rd SARS-CoV-2 mRNA vaccine
Sarah Conway, Shrishti Saxena, Clare Baecher‐Allan, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 2
Open Access | Times Cited: 5
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis
Yolanda Blanco, Domingo Escudero, Cinta Lleixà, et al.
Neurology Neuroimmunology & Neuroinflammation (2023) Vol. 10, Iss. 6
Open Access | Times Cited: 5
Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: Is it still a severe disease?
Paolo Immovilli, Irene Schiavetti, Alessandro Franceschini, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 85, pp. 105547-105547
Closed Access | Times Cited: 1
Clinical effectiveness of coronavirus disease 2019 vaccination in patients with multiple sclerosis stratified by disease‐modifying treatment
Marijke De Troyer, Ann Van Remoortel, Jeroen Van Schependom, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 7
Open Access | Times Cited: 1
Hospitalisations and humoral COVID-19 vaccine response in vaccinated rituximab-treated multiple sclerosis patients
Hilde Marie Torgauten, Therese Bredholt Onyango, Sonja Ljostveit, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 89, pp. 105770-105770
Closed Access | Times Cited: 1
T cell responses to SARS-CoV-2 vaccination differ by disease-modifying therapy for multiple sclerosis
Asia‐Sophia Wolf, Anthony Ravussin, Marton König, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 4
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Lina Jeantin, Basma Abdi, Cathia Soulié, et al.
Journal of Neurology Neurosurgery & Psychiatry (2023) Vol. 95, Iss. 1, pp. 19-28
Closed Access | Times Cited: 4
Risk of breakthrough COVID-19 after vaccination among people with multiple sclerosis on disease-modifying therapies
Ronen Spierer, Idit Lavi, Sivan Bloch, et al.
Journal of Neurology (2023) Vol. 270, Iss. 10, pp. 4632-4639
Closed Access | Times Cited: 4
Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
Saskia Räuber, Alice Willison, Melanie Korsen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 7
Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: Insights from Israel
Janick Weberpals, Spyros Roumpanis, Yael Barer, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104153-104153
Open Access | Times Cited: 6
Humoral and cellular responses to repeated COVID-19 exposure in multiple sclerosis patients receiving B-cell depleting therapies: a single-center, one-year, prospective study
Roberto Alfonso, Jerry Lin, Joyce Lei, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top